



US005266594A

United States Patent [19]

[11] Patent Number: **5,266,594**

Dawson et al.

[45] Date of Patent: **Nov. 30, 1993**

[54] **INHIBITORS OF NITRIC OXIDE SYNTHASE AND USE THEREOF TO PREVENT GLUTAMATE NEUROTOXICITY**

[76] Inventors: **Valina L. Dawson; Ted M. Dawson**, both of 13 Campton Ct., Baltimore, Md. 21236; **Edythe D. London**, 41 Jones Falls Ter., Baltimore, Md. 21209; **David S. Bredt**, 15 Andrews Pl., Baltimore, Md. 21201; **Solomon H. Snyder**, 3801 Canterbury Rd., Apt. 1001, Baltimore, Md. 21218

[21] Appl. No.: **881,900**

[22] Filed: **May 12, 1992**

[51] Int. Cl.⁵ **A61K 31/20**

[52] U.S. Cl. **514/560**

[58] Field of Search **514/560**

[56] **References Cited PUBLICATIONS**

Albin et al., 1990, "Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in pre-symptomatic Huntington's disease," *N. Engl. J. Med.*, 322:1293-1298.

Beal et al., 1991, "Chronic quinolinic acid lesions in rats closely mimic Huntington's disease," *J. Neuroscience*, 11:1649-1659.

Beal et al., 1989, "Quinolinic acid striatal lesions in primates as a model of Huntington's disease," *Ann. Neurol.*, 26:137.

Choi, 1990, "Methods for antagonizing glutamate neurotoxicity," *Cerebrovasc. Brain Metab. Rev.*, 2:105-147.

Choi, 1988, "Glutamate neurotoxicity and diseases of the nervous system," *Neuron*, 1:623-634.

Coyle and Schwarcz, 1976, "Lesions of striatal neurons with kainic acid provides a model for Huntington's chorea," *Nature*, 263:244-246.

Greenamyre et al., 1985, "Alterations in L-glutamate binding in Alzheimer's and Huntington's disease," *Science*, 227:1496-1499.

Gardiner et al., 1990, "Regional and cardiac haemodynamic effects of N^G-nitro-L-arginine methyl ester in

conscious, Long Evans rats," *Br. J. Pharmacol.*, 101(3):625-631.

McGeer and McGeer, 1976, "Alterations in L-glutamate binding in Alzheimer's and Huntington's disease," *Science*, 227:1496-1499.

Plaitakis and Yahr, 1982, "Abnormal glutamate metabolism in an adult-onset degenerative neurological disorder," *Science*, 216:193-196. References Implicating Glutamate Neurotoxicity in Neurodegenerative Disease.

Plaitakis et al., 1988, "The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis," *Ann. Neurol.*, 24:445-449.

Rothstein et al., 1990, "Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis," *Ann. Neurol.*, 28:18-25.

Schwarcz et al., 1983, "Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain," *Science*, 219:316-318.

Young, 1988, "NMDA receptors losses in putamen from patients with Huntington's disease," *Science*, 241:981-983.

Dawson et al., *Proc. Natl. Acad. Sci. USA*, 1991, 88:6368-6371.

Dawson et al., *J. Neuroscience*, in press, 1993.

Nowicki et al., *Eur. J. Pharmac.*, 1991, 204:339-340.

Trifiletti, *Eur. J. Pharmac.* 1992, 218:197-198.

Chem. Abst. 114-59571n (1991).

Useful Information On Alzheimer's Disease, U.S. Dept. HHS (1990).

Primary Examiner—S. J. Friedman
Attorney, Agent, or Firm—Banner, Birch, McKie and Beckett

[57] **ABSTRACT**

Inhibitors of nitric acid synthase can be used to prevent neurotoxicity mediated through glutamate receptors. Nitric oxide synthase inhibitors can be used therapeutically in the treatment of vascular stroke and neurodegenerative disorders such as Alzheimer's disease and Huntington's disease.

18 Claims, 6 Drawing Sheets